Celltrion, Q2 Operating Profit 242.5 Billion... "All-Time High"

[Financial News] Celltrion announced on the 21st that it recorded provisional results of 961.5 billion won in sales and 242.5 billion won in operating profit on a consolidated basis in the second quarter of 2025.
This is an increase of 9.9% and 234.5%, respectively, compared to the same period last year, marking the highest performance on record for the second quarter. The operating profit margin also improved significantly to around 25%.
This performance growth is analyzed to be due to stable sales of existing products in the global market and the expansion of sales of high-profit new products.
In particular, high-margin products such as △Remsima SC (US product name Jimfentra) △Yuflyma △Vegzelma △Stekima have driven the performance increase as they have started to grow in earnest. The sales proportion of high-margin new products expanded significantly from 30% in the same period last year to 53%.
Celltrion expects the strong performance to continue in the second half of the year. This is because four new products, including △Omriclo △Aptozma △Idengel △Stovoclo-Osenbelt, are scheduled to be launched sequentially in major global countries. Through this, the growth in sales and operating profit is expected to be even greater than in the first half.
Efforts to improve profitability are also continuing. Celltrion is rapidly lowering the previously high cost of sales ratio at the time of the merger through methods such as △exhausting high-cost inventory before the merger △improving production yield (TI) △increasing the operation rate of the third plant △reducing outsourcing of raw pharmaceuticals △ending amortization of development costs for existing products.
The cost ratio in the second quarter was about 43%, down about 15 percentage points from the same period last year and 4 percentage points from the previous quarter, contributing to the expansion of profit margins.
This provisional performance announcement was released about half a month earlier than last year. Celltrion explained that it was a proactive measure to quickly announce the strong performance to the market. However, these figures are provisional before accounting review, and the confirmed performance will be separately announced later.
A Celltrion official stated, "Sales have expanded centered on high-profit new products, achieving the highest quarterly performance ever," and added, "In the second half, we plan to further accelerate growth centered on the launch of high-margin new products in the global market."

vrdw88@fnnews.com Kang Jung-mo Reporter